Rheological properties and structure of a semi-solid tin-lead alloy.

Massachusetts Institute of Technology. Dept. of Metallurgy and Materials Science. Thesis. 1974. Ph.D.MICROFICHE COPY ALSO AVAILABLE IN SCIENCE LIBRARY.Leaf number 102 omitted in paging. Vita.Includes bibliographical references.Ph.D

Identification of Oxidized Platinum Single Atoms on Chlorinated Y-Alumina Support by Density Functional Theory Calculations and X-Ray Absorption Spectroscopy

International audienceThe existence and nature of oxidized Pt single atoms (SA) are unraveled on two γ-Al2O3 supported Pt catalysts (0.3 wt%) containing two chlorine contents (0.1 and 1.4 wt%) characterized by HR-HAADF-STEM and HERFD-XANES/EXAFS after a calcination treatment at 520 °C. Pt SA are revealed as PtOxCly complexes where the number of oxygen (x) and chlorine (y) ligands directly depends on the chlorine content. In order to interpret these experimental observations and provide coherent atomic structures for these PtOxCly complexes, the thermodynamic stability of the oxidized Pt SA species supported on the (1 0 0) surface model of γ-Al2O3 is determined by density functional theory (DFT) calculations as a function of the calcination conditions determined by the temperature, and partial pressures of H2O, HCl and O2. It is shown that various ligands such as Cl, OH, O (from the alumina surface or as extra-ligands) and H2O are coordinated to Pt depending on the conditions and chlorine content. Various square planar and square-based pyramidal PtOxCly species such as PtO2, PtOCl2, PtCl4 are found to be stable in calcination conditions, while octahedral Pt(OH)xCl4-x(H2O) are stabilized in XAS recording conditions. The features of these DFT simulated octahedral Pt SA species are successfully compared to XAS data. On one hand, based on thermodynamics arguments, we proposed models of supported complexes in agreement with EXAFS coordination numbers and distances (Pt-O, Pt-Cl and Pt-Al). On the other hand, the simulated XANES spectra at the Pt L3-edge for these complexes match well with the experimental HERFD-XANES and reveal that the bump feature observed between 11575 eV and 11585 eV (post-edge signal) is a tracer of the amount of Cl coordinated to Pt SA

Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial

International audiencePURPOSE Women with gestational trophoblastic tumors (GTT) resistant to single-agent chemotherapy receive alternative chemotherapy regimens, which, although effective, cause considerable toxicity. All GTT subtypes express programmed death-ligand 1 (PD-L1), and natural killer (NK) cells are involved in trophoblast immunosurveillance. Avelumab (anti-PD-L1) induces NK cell-mediated cytotoxicity. The TROPHIMMUN trial assessed avelumab in women with chemotherapy-resistant GTT. METHODS In this phase II multicenter trial (ClinicalTrials.gov identifier: NCT03135769), women with GTT who experienced disease progression after single-agent chemotherapy received avelumab 10 mg/kg intravenously every 2 weeks until human chorionic gonadotropin (hCG) normalization, followed by 3 consolidation cycles. Rate of hCG normalization was the primary endpoint (2-step Simon design). RESULTS Between December 2016 and September 2018, 15 patients were treated. Median age was 34 years; disease stage was I or III in 53.3% and 46.7% of women, respectively; and International Federation of Gynecology and Obstetrics (FIGO) score was 0-4 in 33.3%, 5-6 in 46.7%, and $7 in 20$ 25%) fatigue (33.3%), nausea/vomiting (33.3%), and infusion-related reaction (26.7%). One patient had grade 3 uterine bleeding (treatment unrelated). Eight patients (53.3%) had hCG normalization after a median of 9 avelumab cycles; none subsequently relapsed. Probability of normalization was not associated with disease stage, FIGO score, or baseline hCG. One patient subsequently had a healthy pregnancy. In avelumab-resistant patients (46.7%), hCG was normalized with actinomycin D (42.3%) or combination chemotherapy/surgery (57.1%). CONCLUSION In patients with single-agent chemotherapy-resistant GTT, avelumab had a favorable safety profile and cured approximately 50% of patients. Avelumab could be a new therapeutic option, particularly in patients who would otherwise receive combination chemotherapy

Journée d'Actualité Archéologique en Autunois et en Bourgogne, 18 avril 2014, Autun

International audienceCette brochure vous permettra de redécouvrirl’ensemble des interventions visant àprésenter les résultats des prospections,fouilles préventives et programmées à Autunmais également dans de nombreux chantiersréalisés en Bourgogne

Journée d'Actualité Archéologique en Autunois et en Bourgogne, 18 avril 2014, Autun

International audienceCette brochure vous permettra de redécouvrirl’ensemble des interventions visant àprésenter les résultats des prospections,fouilles préventives et programmées à Autunmais également dans de nombreux chantiersréalisés en Bourgogne

Journée d'Actualité Archéologique en Autunois et en Bourgogne, 18 avril 2014, Autun

International audienceCette brochure vous permettra de redécouvrirl’ensemble des interventions visant àprésenter les résultats des prospections,fouilles préventives et programmées à Autunmais également dans de nombreux chantiersréalisés en Bourgogne

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia

International audienceImportance Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common presentation of coronavirus disease 2019 (COVID-19).Objective To determine whether tocilizumab (TCZ) improves outcomes of patients hospitalized with moderate-to-severe COVID-19 pneumonia.Design, Setting, and Particpants This cohort-embedded, investigator-initiated, multicenter, open-label, bayesian randomized clinical trial investigating patients with COVID-19 and moderate or severe pneumonia requiring at least 3 L/min of oxygen but without ventilation or admission to the intensive care unit was conducted between March 31, 2020, to April 18, 2020, with follow-up through 28 days. Patients were recruited from 9 university hospitals in France. Analyses were performed on an intention-to-treat basis with no correction for multiplicity for secondary outcomes.Interventions Patients were randomly assigned to receive TCZ, 8 mg/kg, intravenously plus usual care on day 1 and on day 3 if clinically indicated (TCZ group) or to receive usual care alone (UC group). Usual care included antibiotic agents, antiviral agents, corticosteroids, vasopressor support, and anticoagulants.Main Outcomes and Measures Primary outcomes were scores higher than 5 on the World Health Organization 10-point Clinical Progression Scale (WHO-CPS) on day 4 and survival without need of ventilation (including noninvasive ventilation) at day 14. Secondary outcomes were clinical status assessed with the WHO-CPS scores at day 7 and day 14, overall survival, time to discharge, time to oxygen supply independency, biological factors such as C-reactive protein level, and adverse events.Results Of 131 patients, 64 patients were randomly assigned to the TCZ group and 67 to UC group; 1 patient in the TCZ group withdrew consent and was not included in the analysis. Of the 130 patients, 42 were women (32%), and median (interquartile range) age was 64 (57.1-74.3) years. In the TCZ group, 12 patients had a WHO-CPS score greater than 5 at day 4 vs 19 in the UC group (median posterior absolute risk difference [ARD] −9.0%; 90% credible interval [CrI], −21.0 to 3.1), with a posterior probability of negative ARD of 89.0% not achieving the 95% predefined efficacy threshold. At day 14, 12% (95% CI −28% to 4%) fewer patients needed noninvasive ventilation (NIV) or mechanical ventilation (MV) or died in the TCZ group than in the UC group (24% vs 36%, median posterior hazard ratio [HR] 0.58; 90% CrI, 0.33-1.00), with a posterior probability of HR less than 1 of 95.0%, achieving the predefined efficacy threshold. The HR for MV or death was 0.58 (90% CrI, 0.30 to 1.09). At day 28, 7 patients had died in the TCZ group and 8 in the UC group (adjusted HR, 0.92; 95% CI 0.33-2.53). Serious adverse events occurred in 20 (32%) patients in the TCZ group and 29 (43%) in the UC group (P = .21).Conclusions and Relevance In this randomized clinical trial of patients with COVID-19 and pneumonia requiring oxygen support but not admitted to the intensive care unit, TCZ did not reduce WHO-CPS scores lower than 5 at day 4 but might have reduced the risk of NIV, MV, or death by day 14. No difference on day 28 mortality was found. Further studies are necessary for confirming these preliminary results.Trial Registration ClinicalTrials.gov Identifier: NCT0433180

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

International audienc